Sun extends offer for Taro once more
India's Sun Pharmaceutical Industries has once again extended the expiration date of its tender offer to purchase all outstanding shares of Israel-based Taro, in the latest installment of the ongoing dispute (Marketletters passim).
The offer will now expire at 5:00 pm, New York City time, on April 3, 2009, unless further extended or earlier terminated. The offer was extended to comply with a continuing order issued by the Supreme Court of Israel prohibiting closing until it issues a decision on an appeal of litigation against Sun by Taro and regarding the applicability of the special tender offer rules. The Tel-Aviv District Court had previously ruled in favor of Sun that a special tender offer was not required.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze